
WHAT IS CLAIMED IS:

1. Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide.

2. The salt of Claim 1, wherein the salt is described by Formula (II)



(II).

3. The salt of Claim 1 in a non-hydrate form.

4. The salt of Claim 1 in a hydrate form.

5. A pharmaceutical composition comprising:

(a) a therapeutically effective amount of a salt according to any of claims 1-4; and

(b) at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient.


6. A method of treating a disease which responds to an inhibition of cyclin dependent kinases activity comprising the step of administering to a subject in need of such treatment a therapeutically effective amount of a salt according to any of claim 1-4.

7. A method of preparing the compound of Formula (I) comprising

WHAT IS CLAIMED IS:

1. Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide.

2. The salt of Claim 1, wherein the salt is described by Formula (II)



(II).

3. The salt of Claim 1 in a non-hydrate form.

4. The salt of Claim 1 in a hydrate form.

5. A pharmaceutical composition comprising:

(a) a therapeutically effective amount of a salt according to any of claims 1-4; and

(b) at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient.

6. The use of a therapeutically effective amount of a salt according to any of claim 1-4 in the manufacture of a medicament for the treatment of a disease which responds to an inhibition of cyclin dependent kinases activity.

7. A method of preparing the compound of Formula (I) comprising